Bedrijfsoverzicht
Cocrystal Pharma, Inc. is a biotechnology entity dedicated to the discovery and development of antiviral therapeutic treatments designed to address serious and chronic viral diseases within the United States market. The company operates specifically within the Healthcare sector and focuses on the Biotechnology industry, a field characterized by high R&D expenditures and significant regulatory hurdles for bringing new molecular entities to market. As of the latest reporting period, the firm maintains a total market capitalization of $17.23M and employs a workforce of 10 individuals to execute its strategic initiatives. The combination of a market cap under $20 million and a lack of reported annual revenue indicates that Cocrystal Pharma is a micro-cap enterprise in the early stages of commercialization or development, relying heavily on external financing or internal reserves rather than current sales streams. This financial profile suggests the company is prioritizing the advancement of its pipeline assets over immediate revenue generation, which is a typical strategic posture for early-stage biotechnology firms seeking to validate their technology before entering the broader commercial phase.
Financiële gezondheid
The company's financial performance over the trailing twelve months reveals a net income of $-8,831,000 and an EBITDA of $-8,947,000, with revenue figures reported as unavailable due to the absence of commercial sales. The substantial gap between the negligible revenue and the significant net losses highlights a cost structure driven almost entirely by operating expenses related to research, development, and general corporate overhead, rather than by cost of goods sold associated with product sales. Free cash flow stands at $-4,946,875, indicating that the company is burning cash at a rate that requires continuous replenishment through equity or debt financing to sustain operations. All three key profitability metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which reflects the lack of revenue generation and the inability to derive profit from sales or operations at this stage. In terms of balance sheet strength, the company holds $7.03M in cash against $1.50M in debt, resulting in a debt-to-equity ratio of 23.77 that suggests a leveraged position relative to its equity base, yet the absolute debt load remains manageable against available liquidity. Liquidity is further supported by a current ratio of 3.68, which indicates that the company possesses more than three times the current assets needed to cover its short-term liabilities, providing a robust buffer against immediate financial obligations. Finally, the return on equity is -111.4% and the return on assets is -48.7%, metrics that reveal that management has not yet generated positive returns on the capital invested in the business, a common characteristic of pre-revenue biotechnology companies still in the value-creation phase.
Waarderingsbeoordeling
Valuation multiples for Cocrystal Pharma present a complex picture given the company's lack of earnings, with a trailing twelve-month P/E ratio listed as N/A and a forward P/E of -1.95. The negative forward P/E implies that analysts or data providers anticipate the company will continue to report losses in the coming year, preventing the calculation of a meaningful earnings-based multiple that would reflect growth expectations. The price-to-book ratio is 2.72, indicating that the market values the company at a premium of 2.72 times its tangible book value, a metric that often reflects intangible assets such as patent portfolios or proprietary technology not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio are unavailable due to the absence of revenue, while the EV/EBITDA stands at -1.31, further confirming that traditional earnings-based valuation models are not applicable for this specific asset. Price action over the last year has seen the stock trade between a 52-week high of $2.67 and a 52-week low of $0.86, meaning the current valuation sits somewhere within this wide range depending on the specific trading day, though the exact current price is not provided in the dataset. The stock exhibits a beta of 1.18, which signifies that the share price is theoretically 18% more volatile than the broader market, a trait typical for small-cap biotechnology stocks that react sharply to clinical trial results or regulatory news.
Growth & Income
Historical growth data for revenue and earnings are both listed as N/A, reflecting the fact that the company has not yet achieved the scale necessary to report year-over-year growth rates in standard financial reporting. Since there is no revenue baseline, it is impossible to calculate a growth percentage, but the implication is that the company is in an investment phase where every dollar spent is intended to advance the development of antiviral drugs rather than fund expansion of current sales. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means that all available cash flow is retained within the company to fund ongoing research and development activities rather than being distributed to shareholders. This reinvestment strategy aligns with the lifecycle of a biotechnology firm that must preserve capital to navigate the high costs of drug discovery and clinical trials before reaching profitability. Consequently, the overall growth and income profile of Cocrystal Pharma is defined entirely by potential future value creation through the successful development of its antiviral therapeutic pipeline, with no current income yield to support investors seeking regular cash distributions.